论文部分内容阅读
目的观察小儿豉翘清热颗粒联合重组人干扰素α’2a(INFα’2a)治疗毛细支气管炎的临床疗效。方法将58例毛细支气管炎患儿随机分为治疗组及对照组,每组29例。2组均予以常规雾化、止咳、平喘综合治疗,并发细菌感染以抗感染治疗。治疗组在此基础上加用小儿豉翘清热颗粒和重组人干扰素α’2a,观察2组患儿的临床症状和体征消失时间。结果治疗组临床总有效率为93.1%,对照组为86.2%,经统计学分析,差异无统计意义(P>0.05);治疗组显效率为75.9%,对照组为48.3%,经统计学分析,差异有统计意义(P<0.05);治疗组临床症状消失时间、肺部体征消失时间及住院时间均明显短于对照组,差异有统计意义(P<0.05或P<0.01)。结论小儿豉翘清热颗粒联合重组人干扰素α’2a辅佐治疗毛细支气管炎,能及时控制症状,缩短疗程和住院时间,值得临床推广。
Objective To observe the clinical efficacy of Xiaoer Qiqiao Qingre granules in combination with recombinant human interferon α’2a (INFα’2a) in the treatment of bronchiolitis. Methods Fifty-eight children with bronchiolitis were randomly divided into treatment group and control group, with 29 cases in each group. Both groups were given conventional aerosol, cough, asthma comprehensive treatment, complicated by bacterial infection in anti-infection treatment. On the basis of the treatment group, the treatment group was treated with Xiaoyao Qiaoqing Qingre granules and recombinant human interferon α’2a to observe the clinical symptoms and signs disappearance time of the two groups. Results The total clinical effective rate was 93.1% in the treatment group and 86.2% in the control group. There was no significant difference between the two groups (P> 0.05). The effective rate was 75.9% in the treatment group and 48.3% in the control group. According to the statistical analysis , The difference was statistically significant (P <0.05). The disappearance time of clinical symptoms, the disappearance of lung signs and hospital stay in the treatment group were significantly shorter than those in the control group (P <0.05 or P <0.01). Conclusion The treatment of bronchiolitis with adjuvant interferon α’2a in children with Qiaoqing Qingre granules can timely control the symptoms, shorten the duration of treatment and hospitalization, and is worthy of clinical promotion.